Gillmore et al reported a staging system for transthyretin-associated cardiac amyloidosis. This can help to identify a patient who may benefit from more aggressive management. The authors are from University College London, Henri Mondor Teaching Hospital and Eastman Dental Institute.
Patient selection: cardiac amyloidosis due to transthyretin
Parameters:
(1) NT-proBNP in ng/L
(2) eGFR in mL per min per 1.73 square meters
Parameter
Finding
Points
NT-proBNP
<= 3,000 ng/L
0
> 3,000 ng/L
1
eGFR
>= 45 mL/min/1.73 sq m
0
< 45 mL/min/1.73 sq m
1
total score =
= SUM(points for both parameters)
Interpretation:
• minimum score: 0
• maximum score: 2
Score
Stage
Median Survival
0
I
69.2 months
1
II
46.7 months
2
III
24.1 months
To read more or access our algorithms and calculators, please log in or register.
